Brief: Ovid Therapeutics Says Phase 1 Study For OV888/GV101 Capsule Meets Its Objective

Ovid Therapeutics

01/07/2024 13:02

July 1 (Reuters) - Ovid Therapeutics Inc  OVID.O :
    * OVID THERAPEUTICS AND GRAVITON BIOSCIENCE ANNOUNCE TOPLINE
DATA
FROM A PHASE 1 CLINICAL TRIAL STUDYING OV888/GV101 CAPSULE, A
POTENTIAL FIRST-IN-CLASS THERAPY FOR CEREBRAL CAVERNOUS
MALFORMATIONS
    * OVID THERAPEUTICS INC - PHASE 1 STUDY FOR OV888/GV101
CAPSULE
MEETS ITS OBJECTIVE
    * OVID THERAPEUTICS INC - NO SERIOUS ADVERSE EVENTS REPORTED
IN
PHASE 1 STUDY
    * OVID: PHASE 2 STUDY FOR TREATMENT OF CEREBRAL CAVERNOUS
MALFORMATIONS IS EXPECTED TO INITIATE IN H2

Source text for Eikon:  ID:nGNXcbZ703 
Further company coverage:  OVID.O 

 ((Reuters.Briefs@thomsonreuters.com;))